1
|
Ullah I, Busch JF, Rabien A, Ergün B, Stamm C, Knosalla C, Hippenstiel S, Reinke P, Kurtz A. Adult Tissue Extracellular Matrix Determines Tissue Specification of Human iPSC-Derived Embryonic Stage Mesodermal Precursor Cells. Adv Sci (Weinh) 2020; 7:1901198. [PMID: 32154066 PMCID: PMC7055561 DOI: 10.1002/advs.201901198] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Revised: 12/02/2019] [Indexed: 06/10/2023]
Abstract
The selection of pluripotent stem cell (PSC)-derived cells for tissue modeling and cell therapy will be influenced by their response to the tissue environment, including the extracellular matrix (ECM). Whether and how instructive memory is imprinted in adult ECM and able to impact on the tissue specific determination of human PSC-derived developmentally fetal mesodermal precursor (P-meso) cells is investigated. Decellularized ECM (dECM) is generated from human heart, kidney, and lung tissues and recellularized with P-meso cells in a medium not containing any differentiation inducing components. While P-meso cells on kidney dECM differentiate exclusively into nephronal cells, only beating clusters containing mature and immature cardiac cells form on heart dECM. No tissue-specific differentiation of P-meso cells is observed on endoderm-derived lung dECM. P-meso-derived endothelial cells, however, are found on all dECM preparations independent of tissue origin. Clearance of heparan-sulfate proteoglycans (HSPG) from dECM abolishes induction of tissue-specific differentiation. It is concluded that HSPG-bound factors on adult tissue-derived ECM are essential and sufficient to induce tissue-specific specification of uncommitted fetal stage precursor cells.
Collapse
Affiliation(s)
- Imran Ullah
- Berlin Institute of Health Center for Regenerative TherapiesCharité Universitätsmedizin BerlinAugustenburger Platz 113353BerlinGermany
| | - Jonas Felix Busch
- Department of UrologyCharité–Universitätsmedizin Berlin10117BerlinGermany
- Berlin Institute for Urologic Research10117BerlinGermany
| | - Anja Rabien
- Department of UrologyCharité–Universitätsmedizin Berlin10117BerlinGermany
- Berlin Institute for Urologic Research10117BerlinGermany
| | - Bettina Ergün
- Department of UrologyCharité–Universitätsmedizin Berlin10117BerlinGermany
- Berlin Institute for Urologic Research10117BerlinGermany
| | - Christof Stamm
- Berlin Institute of Health Center for Regenerative TherapiesCharité Universitätsmedizin BerlinAugustenburger Platz 113353BerlinGermany
- Deutsches Herzzentrum Berlin and German Center for Cardiovascular ResearchAugustenburger Platz 113353BerlinGermany
| | - Christoph Knosalla
- Deutsches Herzzentrum Berlin and German Center for Cardiovascular ResearchAugustenburger Platz 113353BerlinGermany
| | - Stefan Hippenstiel
- Department of Infectiology and PneumonologyCharité–Universitätsmedizin BerlinAugustenburger Platz 113353BerlinGermany
| | - Petra Reinke
- Berlin Institute of Health Center for Regenerative TherapiesCharité Universitätsmedizin BerlinAugustenburger Platz 113353BerlinGermany
| | - Andreas Kurtz
- Berlin Institute of Health Center for Regenerative TherapiesCharité Universitätsmedizin BerlinAugustenburger Platz 113353BerlinGermany
| |
Collapse
|
2
|
Al Ahmad A, Paffrath V, Clima R, Busch JF, Rabien A, Kilic E, Villegas S, Timmermann B, Attimonelli M, Jung K, Meierhofer D. Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation. Cancers (Basel) 2019; 11:cancers11091298. [PMID: 31484429 PMCID: PMC6770591 DOI: 10.3390/cancers11091298] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Revised: 08/29/2019] [Accepted: 08/30/2019] [Indexed: 12/12/2022] Open
Abstract
Papillary renal cell carcinoma (pRCC) is a malignant kidney cancer with a prevalence of 7–20% of all renal tumors. Proteome and metabolome profiles of 19 pRCC and patient-matched healthy kidney controls were used to elucidate the regulation of metabolic pathways and the underlying molecular mechanisms. Glutathione (GSH), a main reactive oxygen species (ROS) scavenger, was highly increased and can be regarded as a new hallmark in this malignancy. Isotope tracing of pRCC derived cell lines revealed an increased de novo synthesis rate of GSH, based on glutamine consumption. Furthermore, profound downregulation of gluconeogenesis and oxidative phosphorylation was observed at the protein level. In contrast, analysis of the The Cancer Genome Atlas (TCGA) papillary RCC cohort revealed no significant change in transcripts encoding oxidative phosphorylation compared to normal kidney tissue, highlighting the importance of proteomic profiling. The molecular characteristics of pRCC are increased GSH synthesis to cope with ROS stress, deficient anabolic glucose synthesis, and compromised oxidative phosphorylation, which could potentially be exploited in innovative anti-cancer strategies.
Collapse
Affiliation(s)
- Ayham Al Ahmad
- Max Planck Institute for Molecular Genetics, Mass Spectrometry Facility, Ihnestrasse 63-73, 14195 Berlin, Germany.
- Fachbereich Biologie, Chemie, Pharmazie, Freie Universität Berlin, Takustraße 3, 14195 Berlin, Germany.
- Berlin Institute for Urologic Research, Charitéplatz 1, 10117 Berlin, Germany.
| | - Vanessa Paffrath
- Max Planck Institute for Molecular Genetics, Mass Spectrometry Facility, Ihnestrasse 63-73, 14195 Berlin, Germany.
- Berlin Institute for Urologic Research, Charitéplatz 1, 10117 Berlin, Germany.
| | - Rosanna Clima
- Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Via E.Orabona, 470126 Bari, Italy.
- Department of Medical and Surgical Sciences-DIMEC, Medical Genetics Unit, University of Bologna, 40126 Bologna, Italy.
| | - Jonas Felix Busch
- Department of Urology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
| | - Anja Rabien
- Department of Urology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
| | - Ergin Kilic
- Institut für Pathologie am Klinikum Leverkusen, Am Gesundheitspark 11, 51375 Leverkusen, Germany.
- Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
| | - Sonia Villegas
- Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
| | - Bernd Timmermann
- Max Planck Institute for Molecular Genetics, Sequencing Core Facility, Ihnestrasse 63-73, 14195 Berlin, Germany.
| | - Marcella Attimonelli
- Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Via E.Orabona, 470126 Bari, Italy.
| | - Klaus Jung
- Berlin Institute for Urologic Research, Charitéplatz 1, 10117 Berlin, Germany.
- Department of Urology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
| | - David Meierhofer
- Max Planck Institute for Molecular Genetics, Mass Spectrometry Facility, Ihnestrasse 63-73, 14195 Berlin, Germany.
| |
Collapse
|
3
|
Ullah I, Abu-Dawud R, Busch JF, Rabien A, Erguen B, Fischer I, Reinke P, Kurtz A. VEGF – Supplemented extracellular matrix is sufficient to induce endothelial differentiation of human iPSC. Biomaterials 2019; 216:119283. [DOI: 10.1016/j.biomaterials.2019.119283] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Revised: 06/11/2019] [Accepted: 06/13/2019] [Indexed: 01/13/2023]
|
4
|
Kürschner G, Zhang Q, Clima R, Xiao Y, Busch JF, Kilic E, Jung K, Berndt N, Bulik S, Holzhütter HG, Gasparre G, Attimonelli M, Babu M, Meierhofer D. Renal oncocytoma characterized by the defective complex I of the respiratory chain boosts the synthesis of the ROS scavenger glutathione. Oncotarget 2017; 8:105882-105904. [PMID: 29285300 PMCID: PMC5739687 DOI: 10.18632/oncotarget.22413] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2017] [Accepted: 09/21/2017] [Indexed: 12/15/2022] Open
Abstract
Renal oncocytomas are rare benign tumors of the kidney and characterized by a deficient complex I (CI) enzyme activity of the oxidative phosphorylation (OXPHOS) system caused by mitochondrial DNA (mtDNA) mutations. Yet, little is known about the underlying molecular mechanisms and alterations of metabolic pathways in this tumor. We compared renal oncocytomas with adjacent matched normal kidney tissues on a global scale by multi-omics approaches, including whole exome sequencing (WES), proteomics, metabolomics, and metabolic pathway simulation. The abundance of proteins localized to mitochondria increased more than 2-fold, the only exception was a strong decrease in the abundance for CI subunits that revealed several pathogenic heteroplasmic mtDNA mutations by WES. We also observed renal oncocytomas to dysregulate main metabolic pathways, shunting away from gluconeogenesis and lipid metabolism. Nevertheless, the abundance of energy carrier molecules such as NAD+, NADH, NADP, ATP, and ADP were significantly higher in renal oncocytomas. Finally, a substantial 5000-fold increase of the reactive oxygen species scavenger glutathione can be regarded as a new hallmark of renal oncocytoma. Our findings demonstrate that renal oncocytomas undergo a metabolic switch to eliminate ATP consuming processes to ensure a sufficient energy supply for the tumor.
Collapse
Affiliation(s)
- Gerrit Kürschner
- Max Planck Institute for Molecular Genetics, Mass Spectrometry Facility, Berlin, Germany.,Technical University of Berlin, Institute of Bioanalytics, Department of Biotechnology, Berlin, Germany
| | - Qingzhou Zhang
- University of Regina, Department of Biochemistry, Regina, Canada
| | - Rosanna Clima
- University of Bari, Department of Biosciences, Biotechnology and Biopharmaceutics, Bari, Italy.,Department of Medical and Surgical Sciences-DIMEC, Medical Genetics Unit, University of Bologna, Bologna, Italy
| | - Yi Xiao
- Max Planck Institute for Molecular Genetics, Mass Spectrometry Facility, Berlin, Germany.,Freie Universität Berlin, Fachbereich Biologie, Chemie, Pharmazie, Berlin, Germany
| | | | - Ergin Kilic
- University Hospital Charité, Institute of Pathology, Berlin, Germany
| | - Klaus Jung
- University Hospital Charité, Department of Urology, Berlin, Germany.,Berlin Institute for Urologic Research, Berlin, Germany
| | - Nikolaus Berndt
- Charité University Medicine Berlin, Institute of Biochemistry Computational Systems Biochemistry Group, Berlin, Germany
| | - Sascha Bulik
- Charité University Medicine Berlin, Institute of Biochemistry Computational Systems Biochemistry Group, Berlin, Germany
| | - Hermann-Georg Holzhütter
- Charité University Medicine Berlin, Institute of Biochemistry Computational Systems Biochemistry Group, Berlin, Germany
| | - Giuseppe Gasparre
- Department of Medical and Surgical Sciences-DIMEC, Medical Genetics Unit, University of Bologna, Bologna, Italy
| | - Marcella Attimonelli
- University of Bari, Department of Biosciences, Biotechnology and Biopharmaceutics, Bari, Italy
| | - Mohan Babu
- University of Regina, Department of Biochemistry, Regina, Canada
| | - David Meierhofer
- Max Planck Institute for Molecular Genetics, Mass Spectrometry Facility, Berlin, Germany
| |
Collapse
|
5
|
Ivanyi P, Koenig J, Trummer A, Busch JF, Seidel C, Reuter CW, Ganser A, Grünwald V. Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival? World J Urol 2015; 34:909-15. [PMID: 26586475 DOI: 10.1007/s00345-015-1707-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Accepted: 10/06/2015] [Indexed: 12/24/2022] Open
Abstract
PURPOSE To evaluate the impact of bone metastasis (BM) onset toward prognosis in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib. METHODS mRCC patients with BM and sunitinib as first targeted therapy between May 2005 and December 2012 were retrospectively analyzed. Patients with synchronous (s) BM or metachronous (m) BM were compared with regard to treatment and outcome [time to clinical progression (TTcP), overall survival (OS), skeletal-related events (SRE)]. Descriptive statistics, Kaplan-Meier estimation of TTcP and OS, Cox regression analyses, and a landmark analysis were administered. RESULTS BM was identified in 127 mRCC patients; thereof, 82 sunitinib-treated patients were analyzed [sBM n = 57 (69.5 %), mBM n = 25 (30.5 %)]. Higher tumor grading (p = 0.029), male predominance (p = 0.02), and less second-line therapy (p = 0.001) were detected in sBM compared to mBM. SRE remained similar between subgroups (p = 0.462). TTcP during sunitinib was similar [median sBM 8.1 (95 % CI 3.9-12.3) vs. mBM 8.7 (95 % CI 2.7-14.8) months, p = 0.903]. OS remained significantly inferior in sBM patients compared to mBM [median sBM 21.1 (95 % CI 16-26.2) months vs. mBM 38.5 (95 % CI 15-62) months, p = 0.001], which was confirmed by landmark analyses at 1.5, 3, 6, 9, and 12 months. However, OS after occurrence of BM was similar in both groups [median sBM 24.2 (95 % CI 17.3-31.1) months vs. mBM 17.2 (95 % CI 8.4-26) months, p = 0.519]. CONCLUSIONS mBM is associated with an improved OS compared to sBM in mRCC with sunitinib treatment, despite similar efficacy of sunitinib treatment in both groups of patients.
Collapse
Affiliation(s)
- P Ivanyi
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany
| | - J Koenig
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany
| | - A Trummer
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany
| | - J F Busch
- Clinic of Urology, University Hospital Berlin, Charité, Berlin, Germany
| | - C Seidel
- Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Eppendorf, Hamburg, Germany
| | - C W Reuter
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany
| | - A Ganser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany
| | - V Grünwald
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.
| |
Collapse
|